Illumina (ILMN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.31
- Estimate
- $1.23
- Surprise
- +6.8%
- Score at report (before → after)
- 4.9 → 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Illumina (ILMN) beat the $1.23 estimate with adjusted EPS of $1.31 — a clear 6.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (4.9/10) to Hold at 5.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ILMN Sell at 4.6/10.
4 of the last 4 quarters beat the estimate; this quarter's +6.8% surprise compares with a +10.1% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: sequencing revenue (92.0%)
- Concentration risk — Supplier: single-source suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $266.89
- Price target
- $306.92
- Stop
- $248.21
- Upside to target
- +15.0%
At 46.1× trailing and 41.8× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
ILMN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $38.56B
- P/E (fwd)
- 41.8
- P/E (ttm)
- 46.1
- 52-week range
- $88.00–$256.17
- Off 52-week high
- -4.2%
- RSI (14)
- 73
- Volume vs avg
- 0.11×
- Score today
- 4.6/10